A team at Edith Cowan University in Perth deployed the technology to monitor people with melanoma and were able to sort them into high risk and low-risk groups.
This has opened the possibility of assessing the prognosis and tailoring the treatment approach "taking into account disease status”, ANGLE investors were told.
Parsortix was also shown to be superior to other methods looked at by the Edith Cowan team at picking up the tell-tale signs of cancer assessed.
"This work clearly demonstrates the promising clinical utility of the Parsortix system for metastatic melanoma prognostication and monitoring treatment response,” said Elin Gray, an associate professor at the university.
“We now intend to progress our work with Parsortix to identify ways in which we can improve the treatment of melanoma patients."
ANGLE chief executive Andrew Newland said the latest update revealed another great example of Parsortix customers developing new cancer applications for the device.
“Melanoma is an important opportunity for future use of Parsortix," he added.
In early trading on Tuesday, shares in ANGLE added 5.8% at 73p.
-- Adds share price --